FCH
TCRT icon

Freestone Capital Holdings’s Alaunos Therapeutics TCRT Stock Holding History

Freestone Capital Holdings’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-67
Closed -$707 – 462
2023
Q4 		$707 Hold
67
– – ﹤0.01% 405
2023
Q3 		$1.32K Hold
67
– – ﹤0.01% 379
2023
Q2 		$5.1K Hold
67
– – ﹤0.01% 393
2023
Q1 		$6.3K Hold
67
– – ﹤0.01% 371
2022
Q4 		$6.49K Hold
67
– – ﹤0.01% 377
2022
Q3 		$17K Hold
67
– – ﹤0.01% 371
2022
Q2 		$12K Hold
67
– – ﹤0.01% 417
2022
Q1 		$7K Hold
67
– – ﹤0.01% 580
2021
Q4 		$11K Buy
+67
New +$14.7K ﹤0.01% 507

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Freestone Capital Holdings's TCRT Position: Q1 2024 in Review

Freestone Capital Holdings sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 67 shares — an estimated $707 sold.

Freestone Capital Holdings first reported a position in TCRT in Q4 2021 and held it in 9 quarters. The position peaked at $17K in Q3 2022. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.

  • Freestone Capital Holdings reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Freestone Capital Holdings sold 67 Alaunos Therapeutics shares in Q1 2024, an estimated $707.
  • Freestone Capital Holdings first reported a position in Alaunos Therapeutics in Q4 2021 and held it in 9 quarters.
  • Freestone Capital Holdings's Alaunos Therapeutics position peaked at $17K in Q3 2022.
  • 45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.

Based on Freestone Capital Holdings's 13F filing for Q1 2024, filed 14 May 2024.